Abstract
We investigated the serum concentration of vascular endothelial growth factor (VEGF) and its two soluble receptors, sVEGFR-1 and sVEGFR-2, in a group of 60 patients with systemic lupus erythematosus (SLE), and 20 healthy controls, using an enzyme-linked immunosorbent assay. We examined a possible association between serum levels of these proteins and certain clinical and laboratory parameters as well as SLE activity. VEGF, sVEGFR-1 and sVEGFR-2 were detectable in all patients with SLE and in all normal individuals. The VEGF level was higher in active SLE (mean, 300.8 pg/ml) than in inactive SLE (mean, 165.9 pg/ml) (p < 0.05) or in the control group (mean, 124.7 pg/ml) (p < 0.04). The highest sVEGFR-1 concentrations were also detected in active SLE patients (mean, 42.2 pg/ml) and the lowest in inactive disease (mean, 32.0 pg/ml) (p < 0.01). In contrast, the levels of sVEGFR-2 were lower in SLE (mean, 12557.6 pg/ml) than in the control group (mean, 15025.3 pg/ml) (p < 0.05). We found a positive correlation between sVEGFR-1 concentration and the SLE activity score p = 0.375 (p < 0.004) and a negative, but statistically insignificant correlation between sVEGFR-2 and SLE activity (p = -0.190, p > 0.05). Treatment with steroids and cytotoxic agents did not influence VEGF or its soluble receptors levels. In conclusion, in SLE patients the levels of VEGF and sVEGFR-1 are higher in patients with active SLE than in inactive disease or healthy persons. In contrast, the level of sVEGFR-2 is lower in active SLE than in inactive disease. The imbalance between VEGF and its soluble receptors may be important in SLE pathogenesis.
Full Text
The Full Text of this article is available as a PDF (110.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barleon B., Reusch P., Totzke F., Herzog C., Keck C., Martiny-Baron G., Marmé D. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis. 2001;4(2):143–154. doi: 10.1023/a:1012245307884. [DOI] [PubMed] [Google Scholar]
- Barleon B., Siemeister G., Martiny-Baron G., Weindel K., Herzog C., Marmé D. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res. 1997 Dec 1;57(23):5421–5425. [PubMed] [Google Scholar]
- Belgore F. M., Lip G. Y., Bareford D., Wadley M., Stonelake P., Blann A. D. Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer. Am J Hematol. 2001 Jan;66(1):59–61. doi: 10.1002/1096-8652(200101)66:1<59::AID-AJH1011>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
- Clauss M., Weich H., Breier G., Knies U., Röckl W., Waltenberger J., Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996 Jul 26;271(30):17629–17634. doi: 10.1074/jbc.271.30.17629. [DOI] [PubMed] [Google Scholar]
- Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997 Feb;18(1):4–25. doi: 10.1210/edrv.18.1.0287. [DOI] [PubMed] [Google Scholar]
- Harada M., Mitsuyama K., Yoshida H., Sakisaka S., Taniguchi E., Kawaguchi T., Ariyoshi M., Saiki T., Sakamoto M., Nagata K. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol. 1998;27(5):377–380. doi: 10.1080/03009749850154429. [DOI] [PubMed] [Google Scholar]
- Harris A. L., Reusch P., Barleon B., Hang C., Dobbs N., Marme D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res. 2001 Jul;7(7):1992–1997. [PubMed] [Google Scholar]
- Hasan J., Jayson G. C. VEGF antagonists. Expert Opin Biol Ther. 2001 Jul;1(4):703–718. doi: 10.1517/14712598.1.4.703. [DOI] [PubMed] [Google Scholar]
- Holash Jocelyn, Davis Sam, Papadopoulos Nick, Croll Susan D., Ho Lillian, Russell Michelle, Boland Patricia, Leidich Ray, Hylton Donna, Burova Elena. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug 12;99(17):11393–11398. doi: 10.1073/pnas.172398299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hornig C., Barleon B., Ahmad S., Vuorela P., Ahmed A., Weich H. A. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest. 2000 Apr;80(4):443–454. doi: 10.1038/labinvest.3780050. [DOI] [PubMed] [Google Scholar]
- Hornig C., Behn T., Bartsch W., Yayon A., Weich H. A. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. J Immunol Methods. 1999 Jun 24;226(1-2):169–177. doi: 10.1016/s0022-1759(99)00065-4. [DOI] [PubMed] [Google Scholar]
- Hornig C., Weich H. A. Soluble VEGF receptors. Angiogenesis. 1999;3(1):33–39. doi: 10.1023/a:1009033017809. [DOI] [PubMed] [Google Scholar]
- Houck K. A., Ferrara N., Winer J., Cachianes G., Li B., Leung D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991 Dec;5(12):1806–1814. doi: 10.1210/mend-5-12-1806. [DOI] [PubMed] [Google Scholar]
- Jośko J., Gwódź B., Jedrzejowska-Szypułka H., Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit. 2000 Sep-Oct;6(5):1047–1052. [PubMed] [Google Scholar]
- Kadono T., Kikuchi K., Kubo M., Fujimoto M., Tamaki K. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol. 1996 Sep;35(3 Pt 1):392–397. doi: 10.1016/s0190-9622(96)90603-9. [DOI] [PubMed] [Google Scholar]
- Kendall R. L., Wang G., Thomas K. A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996 Sep 13;226(2):324–328. doi: 10.1006/bbrc.1996.1355. [DOI] [PubMed] [Google Scholar]
- Liang M. H., Socher S. A., Larson M. G., Schur P. H. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989 Sep;32(9):1107–1118. doi: 10.1002/anr.1780320909. [DOI] [PubMed] [Google Scholar]
- Lin P., Sankar S., Shan S., Dewhirst M. W., Polverini P. J., Quinn T. Q., Peters K. G. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 1998 Jan;9(1):49–58. [PubMed] [Google Scholar]
- Meeson A. P., Argilla M., Ko K., Witte L., Lang R. A. VEGF deprivation-induced apoptosis is a component of programmed capillary regression. Development. 1999 Apr;126(7):1407–1415. doi: 10.1242/dev.126.7.1407. [DOI] [PubMed] [Google Scholar]
- Plate K. H., Warnke P. C. Vascular endothelial growth factor. J Neurooncol. 1997 Dec;35(3):365–372. doi: 10.1023/a:1005845307160. [DOI] [PubMed] [Google Scholar]
- Risau W. Mechanisms of angiogenesis. Nature. 1997 Apr 17;386(6626):671–674. doi: 10.1038/386671a0. [DOI] [PubMed] [Google Scholar]
- Robak E., Woźniacka A., Sysa-Jedrzejowska A., Stepień H., Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus. 2002;11(6):348–355. doi: 10.1191/0961203302lu199oa. [DOI] [PubMed] [Google Scholar]
- Robak E., Woźniacka A., Sysa-Jedrzejowska A., Stepień H., Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cytokine Netw. 2001 Jul-Sep;12(3):445–452. [PubMed] [Google Scholar]
- Robak T., Wierzbowska A., Błasińska-Morawiec M., Korycka A., Błoński J. Z. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Mediators Inflamm. 1999;8(6):277–286. doi: 10.1080/09629359990289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roeckl W., Hecht D., Sztajer H., Waltenberger J., Yayon A., Weich H. A. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res. 1998 May 25;241(1):161–170. doi: 10.1006/excr.1998.4039. [DOI] [PubMed] [Google Scholar]
- Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol. 2001 Apr;33(4):409–420. doi: 10.1016/s1357-2725(01)00026-7. [DOI] [PubMed] [Google Scholar]
- Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990 Apr;5(4):519–524. [PubMed] [Google Scholar]
- Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
- Terman B. I., Dougher-Vermazen M., Carrion M. E., Dimitrov D., Armellino D. C., Gospodarowicz D., Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579–1586. doi: 10.1016/0006-291x(92)90483-2. [DOI] [PubMed] [Google Scholar]
- Toi Masakazu, Bando Hiroko, Ogawa Taeko, Muta Mariko, Hornig Carsten, Weich Herbert A. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer. 2002 Mar 1;98(1):14–18. doi: 10.1002/ijc.10121. [DOI] [PubMed] [Google Scholar]
- Wierzbowska Agnieszka, Robak Tadeusz, Wrzesień-Kuś Agata, Krawczyńska Anna, Lech-Marańda Ewa, Urbańska-Ryś Halina. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw. 2003 Jul-Sep;14(3):149–153. [PubMed] [Google Scholar]
- Yamaguchi Sachiko, Iwata Kumi, Shibuya Masabumi. Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Commun. 2002 Mar 1;291(3):554–559. doi: 10.1006/bbrc.2002.6478. [DOI] [PubMed] [Google Scholar]
- Yancopoulos G. D., Davis S., Gale N. W., Rudge J. S., Wiegand S. J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000 Sep 14;407(6801):242–248. doi: 10.1038/35025215. [DOI] [PubMed] [Google Scholar]
- de Vries C., Escobedo J. A., Ueno H., Houck K., Ferrara N., Williams L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992 Feb 21;255(5047):989–991. doi: 10.1126/science.1312256. [DOI] [PubMed] [Google Scholar]